Ouch: Treatt’s Profit Warning Sours the Mood
Well, this isn’t the update Treatt investors were hoping for. The flavour and fragrance ingredients specialist has just served up a significant profit warning, sharply downgrading its expectations for the full year ending September 2025 (FY2025). The numbers make for sobering reading.
The Numbers: A Significant Downgrade
Treatt now expects:
- Revenue: £130m – £135m (previously guided at £146m – £153m)
- Profit Before Tax & Exceptionals (PBTE): £9m – £11m (previously guided at £16m – £18m)
That’s a revenue shortfall of around 10-12% and, more painfully, a projected profit drop of 38-44% compared to previous guidance issued just three months ago in April. The second half revenue forecast has been particularly savaged, now expected at £66m versus the previous £82m.
Why the Sudden Squeeze?
Management points to a confluence of incremental pressures since their May interims:
1. Slower Sales Conversion & Weak Volumes:
- While securing some promising new customer wins (especially in the Premium segment), converting the overall sales pipeline has been “slower than anticipated”.
- Repeat business from existing customers has declined, hit by competitive pressures and dampened North American consumer confidence.
2. Currency Headwinds:
The weaker US Dollar has translated into a c.£0.5m profit hit. Not the main culprit, but certainly unhelpful.
3. Lingering Issues from the Interims:
Two previously flagged problems haven’t gone away:
- Citrus Conundrum: Persistently high citrus oil prices have continued to disrupt the Heritage division. Customers are reformulating products and holding back on orders for value-added citrus products, impacting both volumes and margins. While prices are *starting* to fall, the damage for FY2025 is done.
- North American Nerves: Geopolitical uncertainty, tariff concerns, and shaky consumer confidence in the US have led to an “extended softening of demand” in the key North American beverage market.
Mitigation and the Road Ahead
Treatt emphasises its self-help measures:
- Focus on “simplification and efficiency gains” to counter inflation and protect investment in growth areas.
- Admin expenses are expected to be flat year-on-year.
- The £5m share buyback was completed in May.
The balance sheet remains a relative bright spot, though the lower profits mean they now expect a low net debt position at year-end (versus previous guidance of £1m-£3m net cash).
Strategically, Treatt insists it’s still on track:
- Commitment to growth via customer focus, market expansion, and innovation (highlighting the planned Shanghai innovation centre opening).
- Strengthening senior teams for new markets and opportunities.
- Claiming a strengthened sales pipeline for FY2026 and beyond, targeting better margins.
The Bottom Line: A Bitter Pill
This is undeniably a tough update. The scale of the profit downgrade is significant and points to deeper challenges than perhaps anticipated just a few months ago. While external factors (citrus prices, US confidence, FX) play a role, the admission of slower sales conversion and competitive pressures on repeat volumes is crucial. The “self-help” measures clearly haven’t been enough to offset these headwinds in FY2025.
The key questions for investors now are:
- How quickly will the citrus market normalisation actually flow through to improved Treatt performance?
- Is the North American softness a temporary blip or a more structural shift affecting Treatt’s core markets?
- Can the “strengthened pipeline” convert into tangible, profitable growth swiftly in FY2026 to justify the current strategy and investments?
Treatt’s story of supplying natural ingredients for evolving consumer tastes remains compelling long-term. But today’s announcement is a stark reminder of the near-term volatility and competitive intensity within their supply chain and end markets. Investors will be looking for concrete signs of recovery and pipeline conversion in the next updates. The flavour of the day is decidedly cautious.
